Even with those alarming numbers, the US FDA approvals of disease-modifying therapies (DMTs) such as Leqembi (lecanemab) and ...

The expansion forms part of Lilly’s broader $50bn capital investment programme to grow its US manufacturing and production ...

Novartis has reported new results from two ongoing phase 3 trials evaluating ianalumab in patients with Sjögren’s disease, ...

UCB, a global biopharmaceutical company, has announced the final results from its open-label extension (OLE) study evaluating ...

Kyowa Kirin, the European subsidiary of the Japan-based specialty pharmaceutical company, and University Hospitals Birmingham ...

Metro maps in unfamiliar cities offer a complex, often – confusing, matrix of opportunities with their twisting lines, but ...

Today, four out of five HCPs say they’re using LLMs to support clinical decision-making. As these LLM models solidify their ...

GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...

Medicus Pharma, a biotech and life sciences company developing novel and disruptive therapeutics, has announced the enrolment ...

Aqilion, a Swedish biopharma company developing therapies for diseases driven by chronic inflammation and dysregulated immune ...

The GPPG is more than a publication – it’s a movement towards truly patient- centric and accessible healthcare. It aims to ...

Sanofi has reported that the high-dose formulation of its influenza vaccine, Elfueda (known as Fluzone High-Dose in the US), ...